The development of myopericarditis following COVID-19 vaccination appears to be rare in the general population, according to the findings of a systematic review and meta-analysis recently published in The Lancet Respiratory Medicine.

As cases of myopericarditis following COVID-19 vaccine administration have been reported, the researchers aimed to determine the incidence of this condition following administration of different vaccines. They searched 4 international databases for studies reporting on the development of myopericarditis in temporal relation to vaccination in the general population.

“We analyzed the difference in incidence of myopericarditis among subpopulations, stratifying by the type of vaccine (COVID-19 vsnon-COVID-19) and age group (adult vspediatric),” the authors explained. “Among COVID-19 vaccinations, we examined the effect of the type of vaccine (mRNA or non-mRNA), sex, age, and dose on the incidence of myopericarditis.”

The analysis included data from 22 studies (405,272,721 vaccine doses); 11 of which looked at COVID-19 vaccination specifically, covering over 395 million doses. Overall, the incidence of myopericarditis was found to be 33.3 cases per million doses (95% CI, 15.3-72.6).

Findings of the analysis did not reveal a significant difference in the incidence of myopericarditis between patients who received COVID-19 vaccines (18.2 cases per million doses; 95% CI, 10.9–30.3) and those who received other vaccines (56.0 cases per million doses; 95% CI, 10.7–293.7; P =.20).

Among patients administered a COVID-19 vaccine, myopericarditis risk was higher for those who received an mRNA vaccine (22.6 cases per million doses) compared with a non-mRNA vaccine (7.9 cases per million doses). Receiving a second dose of COVID-19 vaccine was also linked to increased risk (31.1 cases per million doses), as was younger age (patients under 30 years old; 40.9 cases per million doses) and being male (23 cases per million doses).

“Our research suggests that the overall risk of myopericarditis appears to be no different for this newly approved group of vaccines against COVID- 19, compared to vaccines against other diseases,” said Dr Kollengode Ramanathan, a cardiac intensivist at National University Hospital, Singapore, and corresponding author. “The risk of such rare events should be balanced against the risk of myopericarditis from infection and these findings should bolster public confidence in the safety of COVID-19 vaccinations.”

Reference

Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non- COVID-19 vaccination: a systematic review and meta- analysis. Lancet Respir Med. Published online April 11, 2022. doi: https://doi.org/10.1016/ S2213-2600(22)00059-5